Cargando…
Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?
Whilst literature is expanding on pasireotide use in the management of Cushing’s disease (CD), there is still currently much unknown about long-term and low-dose pasireotide use in CD. We present a 60-year-old female with residual CD after transphenoidal surgery (TSS), being successfully managed wit...
Autores principales: | Wong, Mimi, Malabu, Usman H, Korah, Ipeson, Tan, YongMong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923187/ https://www.ncbi.nlm.nih.gov/pubmed/33865235 http://dx.doi.org/10.1530/EDM-20-0206 |
Ejemplares similares
-
Efficacy of pasireotide in controlling severe hypercortisolism until cardiac transplantation
por: Attanasio, Roberto, et al.
Publicado: (2017) -
Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma
por: Rajendran, Rajesh, et al.
Publicado: (2013) -
Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia
por: Gordon, Murray B, et al.
Publicado: (2017) -
Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017) -
Osilodrostat in Cushing’s disease: the management of its efficacy and the pitfalls of post-surgical results
por: Antonini, Simone, et al.
Publicado: (2022)